Receive The Newest Study Notifications

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the dosing of the first patient in its Phase 1b/2a clinical trial of AB-2004....

SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS) MONTPELLIER, France, July 16, 2019 /PRNewswire/ -- SurgiMab, a late-stage biotechnology company pioneering a new antibody-based...

- Long acting Relaxin is powered by Ambrx technology Ambrx Inc. today announced that Bristol-Myers Squibb Company ("BMS") has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential...

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple cancers. The trial would reportedly be led by one of the world’s leading cancer...

– 87% reduction in average number of Gb3 inclusions in first kidney biopsy taken one year post-treatment, the primary efficacy endpoint in the Phase 2 trial – Plasma lyso-Gb3 consistently reduced 33% to 41% below baseline enzyme replacement therapy (ERT) levels in the...

anssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners is set to initiate a Phase III clinical trial to evaluate an investigational preventive vaccine for HIV-1 infection. The mosaic-based vaccine has been designed to...

- Evaluation in healthy subjects includes biomarker data demonstrating CNS penetration and target engagement Athira Pharma, Inc., a clinical-stage company dedicated to developing first-in-class therapies for Alzheimer's and Parkinson's that are focused on...

CD19 CAR-T candidate, AVA-001, has entered first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in July 2019 Next-generation, transposon-engineered, multi-targeted CAR-T candidate, AVA-101, has entered...

- Rimegepant Zydis® Orally Dissolving Tablet (ODT) formulation demonstrates earlier onset of action than seen previously with standard tablet formulation - Single-dose, proprietary, Zydis ODT provided rapid onset of pain relief with numerical separation from placebo...

An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as Kellgren-Lawrence (KL) Grades 2-4 >80% of KL Grade 4 patients entering the trial with moderate...

-A Retrospective Study on Congenital Disorders of Glycosylation Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today...

Original metastatic castration-resistant prostate cancer and immunotherapy-refractory non-small cell lung cancer cohorts expanded to 80 subjects Four cohorts added for metastatic castration-resistant prostate cancer based on encouraging early data ALAMEDA,...

Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company recently dosed the first patient successfully in a Phase I...

Top-line efficacy data expected to be announced during the Third Quarter of 2019 Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced...

Clinical Trial Enrolled Over 8,200 Patients With Reduced Ejection Fraction in 35 Countries ving with heart failure, these patients continue to suffer from high morbidity and mortality,” said John Teerlink, M.D., Professor of Clinical Medicine, University of California...

6-Month Data from Proof of Concept Clinical Trial Show Average Cellulite Severity Scores Continued to Improve After Single 20-Minute Non-Invasive Procedure of this treatment landscape, our results that not only lasted 6 months, but actually improved 20% on the GAIS...

-Propanc Biopharma, Inc. (OTC: PPCBD) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today an update on Propanc’s preparation of PRP, its anti-cancer lead product...

Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update for its on-going Phase 2...

July 15, 2019 11:00 UTC 87% reduction in average number of Gb3 inclusions in first kidney biopsy taken one year post-treatment, the primary efficacy endpoint in the Phase 2 trial Plasma lyso-Gb3 consistently reduced 33% to 41% below baseline enzyme replacement therapy...

--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled Study -- --Company to Hold Conference Call Today at 5:00 AM PT / 8:00 AM...